A Randomized Controlled Phase II/III Clinical Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06891833

Title field or adapter rule

{'original_value': 'A Randomized Controlled Phase II/III Clinical Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:30.668476+00:00

Published At

2026-10-27T00:00:00+00:00

Record Updated At

2026-10-27

Source Retrieved At

2026-10-31T22:18:24.976182+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["HER2-positive Breast Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-27", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06891833"

protocolSection.identificationModule.officialTitle

"A Randomized Controlled Phase II/III Clinical Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2", "PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• HER2-positive Breast Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Study treatment'], 'description': 'Administration by intravenous infusion for a cycle of 3 weeks.', 'name': 'BL-M07D1', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Study treatment', 'docetaxel + carboplatin + trastuzumab + pertuzumab'], 'description': 'Administration by intravenous infusion for a cycle of 3 weeks.', 'name': 'Pertuzumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['docetaxel + carboplatin + trastuzumab + pertuzumab'], 'description': 'Administration by intravenous infusion for a cycle of 3 weeks.', 'name': 'docetaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['docetaxel + carboplatin + trastuzumab + pertuzumab'], 'description': 'Administration by intravenous infusion for a cycle of 3 weeks.', 'name': 'carboplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['docetaxel + carboplatin + trastuzumab + pertuzumab'], 'description': 'Administration by intravenous infusion for a cycle of 3 weeks.', 'name': 'trastuzumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• BL-M07D1 (protocolSection.armsInterventionsModule.interventions[].name)
• Pertuzumab (protocolSection.armsInterventionsModule.interventions[].name)
• docetaxel (protocolSection.armsInterventionsModule.interventions[].name)
• carboplatin (protocolSection.armsInterventionsModule.interventions[].name)
• trastuzumab (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.